Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
STEMJOINT: Allogenic AD-MSC for Knee Osteoarthritis
NCT05933434Phase 2Recruiting
- Sponsor
- Aarhus University Hospital
- Start
- Mar 2024
- Primary completion
- Oct 2030
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CSCC_ASC in knee osteoarthritis (OA) (2 arms), sponsored by Aarhus University Hospital. Primary endpoints: Observation (change) of adverse events at 5 years and Change in Knee symptoms (questionnaire Knee injury and Osteoarthritis Outcome Score (KOOS) (symptoms)) at 5 years. Started Mar 2024; status: recruiting.
02
Drugs
CSCC_ASC
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05933434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05933434.